{"entity":{"id":"jeffrey-weber","kind":"person","name":"Jeffrey S. Weber","aka":[],"tldr":"Led CheckMate 238, which made adjuvant nivolumab standard after melanoma surgery, and co-led the mRNA vaccine trial KEYNOTE-942.","summary":"Jeffrey Weber was principal investigator of CheckMate 238, which showed adjuvant nivolumab beats ipilimumab in resected stage III-IV melanoma with far less toxicity, and of KEYNOTE-942, the randomised trial showing the individualised mRNA neoantigen vaccine mRNA-4157 plus pembrolizumab reduces recurrence versus pembrolizumab alone. He has led immunotherapy development since the interleukin-2 era and directs melanoma research at NYU.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Weber%20JS%5BAuthor%5D%20melanoma%20adjuvant"}],"tags":["melanoma","adjuvant","vaccine"],"related":[],"cancers":["melanoma"],"sections":[],"technologies":["checkpoint-inhibitor","neoantigen-mrna-vaccine"],"targets":["pd1"],"drugs":["nivolumab","ipilimumab","intismeran-autogene","pembrolizumab"],"companies":[],"institutions":["nyu-perlmutter"],"pathways":[],"terms":[],"trials":["interpath-001"],"people":[],"bottlenecks":[],"keyPapers":["paper-keynote-942-lancet-2024"],"journals":[],"dependsOn":[],"notes":[],"role":"Deputy Director, NYU Langone Perlmutter Cancer Center; Professor of Medicine","institutionId":"nyu-perlmutter","specialisms":["Melanoma","Adjuvant immunotherapy","Cancer vaccines","Tumour immunology"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Weber%20JS%5BAuthor%5D%20melanoma%20adjuvant"}],"papers":[{"title":"Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma (CheckMate 238)","journal":"NEJM","year":2017,"doi":"10.1056/NEJMoa1709030"},{"title":"Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942)","journal":"Lancet","year":2024,"doi":"10.1016/S0140-6736(23)02268-7"},{"title":"KEYNOTE-942: a personalised mRNA cancer vaccine plus pembrolizumab after melanoma surgery","journal":"The Lancet","year":2024,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=mRNA-4157+V940+pembrolizumab+melanoma+KEYNOTE-942+Lancet"}]},"route":"/people/jeffrey-weber/","neighbours":{"cancer":[{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"},{"id":"stage-iii-melanoma","kind":"cancer","name":"Stage III melanoma (after surgery)","route":"/cancers/stage-iii-melanoma/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"neoantigen-mrna-vaccine","kind":"technology","name":"Personalised neoantigen (mRNA) vaccines","route":"/technologies/neoantigen-mrna-vaccine/"}],"target":[{"id":"pd1","kind":"target","name":"PD-1","route":"/targets/pd1/"}],"drug":[{"id":"intismeran-autogene","kind":"drug","name":"Intismeran autogene","route":"/drugs/intismeran-autogene/"},{"id":"ipilimumab","kind":"drug","name":"Ipilimumab","route":"/drugs/ipilimumab/"},{"id":"nivolumab","kind":"drug","name":"Nivolumab","route":"/drugs/nivolumab/"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"}],"institution":[{"id":"nyu-perlmutter","kind":"institution","name":"Laura and Isaac Perlmutter Cancer Center at NYU Langone Health","route":"/institutions/nyu-perlmutter/"}],"trial":[{"id":"checkmate-238","kind":"trial","name":"CheckMate 238","route":"/trials/checkmate-238/"},{"id":"checkmate-915","kind":"trial","name":"CheckMate 915","route":"/trials/checkmate-915/"},{"id":"interpath-001","kind":"trial","name":"INTerpath-001 (V940-001)","route":"/trials/interpath-001/"}],"paper":[{"id":"paper-keynote-942-lancet-2024","kind":"paper","name":"KEYNOTE-942: a personalised mRNA cancer vaccine plus pembrolizumab after melanoma surgery","route":"/key-papers/paper-keynote-942-lancet-2024/"}]}}